Agricultural Inputs
Compare Stocks
2 / 10Stock Comparison
BIOX vs AVD
Revenue, margins, valuation, and 5-year total return — side by side.
Agricultural Inputs
BIOX vs AVD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Agricultural Inputs | Agricultural Inputs |
| Market Cap | $30M | $86M |
| Revenue (TTM) | $318M | $523M |
| Net Income (TTM) | $-53M | $-46M |
| Gross Margin | 39.1% | 29.2% |
| Operating Margin | 0.2% | 1.1% |
| Forward P/E | — | 7.9x |
| Total Debt | $277M | $191M |
| Cash & Equiv. | $33M | $12M |
BIOX vs AVD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Bioceres Crop Solut… (BIOX) | 100 | 7.1 | -92.9% |
| American Vanguard C… (AVD) | 100 | 22.6 | -77.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BIOX vs AVD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
BIOX is the clearest fit if your priority is efficiency.
- -6.7% ROA vs AVD's -7.1%, ROIC -0.5% vs 1.3%
AVD carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 0 yrs, beta 1.17, yield 2.9%
- Rev growth -5.9%, EPS growth 61.1%, 3Y rev CAGR -5.5%
- -71.7% 10Y total return vs BIOX's -95.1%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | -5.9% revenue growth vs BIOX's -28.3% | |
| Quality / Margins | -8.7% margin vs BIOX's -16.6% | |
| Stability / Safety | Beta 1.17 vs BIOX's 1.94 | |
| Dividends | 2.9% yield; the other pay no meaningful dividend | |
| Momentum (1Y) | -27.4% vs BIOX's -88.5% | |
| Efficiency (ROA) | -6.7% ROA vs AVD's -7.1%, ROIC -0.5% vs 1.3% |
BIOX vs AVD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
BIOX vs AVD — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
AVD leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
AVD is the larger business by revenue, generating $523M annually — 1.6x BIOX's $318M. AVD is the more profitable business, keeping -8.7% of every revenue dollar as net income compared to BIOX's -16.6%. On growth, AVD holds the edge at +6.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $318M | $523M |
| EBITDAEarnings before interest/tax | $21M | $20M |
| Net IncomeAfter-tax profit | -$53M | -$46M |
| Free Cash FlowCash after capex | $37M | -$41M |
| Gross MarginGross profit ÷ Revenue | +39.1% | +29.2% |
| Operating MarginEBIT ÷ Revenue | +0.2% | +1.1% |
| Net MarginNet income ÷ Revenue | -16.6% | -8.7% |
| FCF MarginFCF ÷ Revenue | +11.5% | -7.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | -16.4% | +6.7% |
| EPS Growth (YoY)Latest quarter vs prior year | -37.3% | +53.3% |
Valuation Metrics
Evenly matched — BIOX and AVD each lead in 2 of 4 comparable metrics.
Valuation Metrics
On an enterprise value basis, AVD's 10.4x EV/EBITDA is more attractive than BIOX's 20.0x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $30M | $86M |
| Enterprise ValueMkt cap + debt − cash | $274M | $265M |
| Trailing P/EPrice ÷ TTM EPS | -0.58x | -1.71x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 7.89x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 20.01x | 10.45x |
| Price / SalesMarket cap ÷ Revenue | 0.09x | 0.17x |
| Price / BookPrice ÷ Book value/share | 0.10x | 0.44x |
| Price / FCFMarket cap ÷ FCF | 0.85x | — |
Profitability & Efficiency
AVD leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
BIOX delivers a -16.7% return on equity — every $100 of shareholder capital generates $-17 in annual profit, vs $-22 for AVD. BIOX carries lower financial leverage with a 0.94x debt-to-equity ratio, signaling a more conservative balance sheet compared to AVD's 0.99x. On the Piotroski fundamental quality scale (0–9), AVD scores 6/9 vs BIOX's 3/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -16.7% | -21.9% |
| ROA (TTM)Return on assets | -6.7% | -7.1% |
| ROICReturn on invested capital | -0.5% | +1.3% |
| ROCEReturn on capital employed | -0.8% | +1.7% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 6 |
| Debt / EquityFinancial leverage | 0.94x | 0.99x |
| Net DebtTotal debt minus cash | $244M | $179M |
| Cash & Equiv.Liquid assets | $33M | $12M |
| Total DebtShort + long-term debt | $277M | $191M |
| Interest CoverageEBIT ÷ Interest expense | -0.07x | 0.31x |
Total Returns (Dividends Reinvested)
AVD leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in AVD five years ago would be worth $1,664 today (with dividends reinvested), compared to $317 for BIOX. Over the past 12 months, AVD leads with a -27.4% total return vs BIOX's -88.5%. The 3-year compound annual growth rate (CAGR) favors AVD at -44.5% vs BIOX's -64.0% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -65.0% | -21.3% |
| 1-Year ReturnPast 12 months | -88.5% | -27.4% |
| 3-Year ReturnCumulative with dividends | -95.3% | -82.9% |
| 5-Year ReturnCumulative with dividends | -96.8% | -83.4% |
| 10-Year ReturnCumulative with dividends | -95.1% | -71.7% |
| CAGR (3Y)Annualised 3-year return | -64.0% | -44.5% |
Risk & Volatility
AVD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
AVD is the less volatile stock with a 1.17 beta — it tends to amplify market swings less than BIOX's 1.94 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AVD currently trades 50.7% from its 52-week high vs BIOX's 9.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.94x | 1.17x |
| 52-Week HighHighest price in past year | $5.18 | $5.92 |
| 52-Week LowLowest price in past year | $0.35 | $2.05 |
| % of 52W HighCurrent price vs 52-week peak | +9.1% | +50.7% |
| RSI (14)Momentum oscillator 0–100 | 44.6 | 51.4 |
| Avg Volume (50D)Average daily shares traded | 804K | 364K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
AVD is the only dividend payer here at 2.94% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $17.00 |
| # AnalystsCovering analysts | — | 13 |
| Dividend YieldAnnual dividend ÷ price | — | +2.9% |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | $0.09 |
| Buyback YieldShare repurchases ÷ mkt cap | +3.1% | +1.7% |
AVD leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 1 category is tied.
BIOX vs AVD: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is BIOX or AVD a better buy right now?
For growth investors, American Vanguard Corporation (AVD) is the stronger pick with -5.
9% revenue growth year-over-year, versus -28. 3% for Bioceres Crop Solutions Corp. (BIOX). Analysts rate American Vanguard Corporation (AVD) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — BIOX or AVD?
Over the past 5 years, American Vanguard Corporation (AVD) delivered a total return of -83.
4%, compared to -96. 8% for Bioceres Crop Solutions Corp. (BIOX). Over 10 years, the gap is even starker: AVD returned -71. 7% versus BIOX's -95. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — BIOX or AVD?
By beta (market sensitivity over 5 years), American Vanguard Corporation (AVD) is the lower-risk stock at 1.
17β versus Bioceres Crop Solutions Corp. 's 1. 94β — meaning BIOX is approximately 66% more volatile than AVD relative to the S&P 500. On balance sheet safety, Bioceres Crop Solutions Corp. (BIOX) carries a lower debt/equity ratio of 94% versus 99% for American Vanguard Corporation — giving it more financial flexibility in a downturn.
04Which is growing faster — BIOX or AVD?
By revenue growth (latest reported year), American Vanguard Corporation (AVD) is pulling ahead at -5.
9% versus -28. 3% for Bioceres Crop Solutions Corp. (BIOX). On earnings-per-share growth, the picture is similar: American Vanguard Corporation grew EPS 61. 1% year-over-year, compared to -1704. 7% for Bioceres Crop Solutions Corp.. Over a 3-year CAGR, BIOX leads at 0. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — BIOX or AVD?
American Vanguard Corporation (AVD) is the more profitable company, earning -9.
7% net margin versus -15. 5% for Bioceres Crop Solutions Corp. — meaning it keeps -9. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AVD leads at 1. 3% versus -1. 1% for BIOX. At the gross margin level — before operating expenses — BIOX leads at 39. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — BIOX or AVD?
In this comparison, AVD (2.
9% yield) pays a dividend. BIOX does not pay a meaningful dividend and should not be held primarily for income.
07Is BIOX or AVD better for a retirement portfolio?
For long-horizon retirement investors, American Vanguard Corporation (AVD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
17), 2. 9% yield). Bioceres Crop Solutions Corp. (BIOX) carries a higher beta of 1. 94 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AVD: -71. 7%, BIOX: -95. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between BIOX and AVD?
Both stocks operate in the Basic Materials sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
AVD pays a dividend while BIOX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.